Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

GLPG0259 in Methotrexate-refractory Rheumatoid Arthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01211249
Recruitment Status : Completed
First Posted : September 29, 2010
Last Update Posted : April 26, 2011
Information provided by:
Galapagos NV

Brief Summary:

Part A: 30 patients suffering from active rheumatoid arthritis despite continued treatment with methotrexate will receive once daily two capsules containing either GLPG0259 (25 mg/capsule) or matching placebo, for 12 weeks. In the course of the study the patients will be examined for severity of disease, as well as for any adverse effects that may occur. If needed, dosing may be split to one capsule twice daily, or reduced to one capsule of 25 mg.

Part B: If results of Part A suggest test medication to have a therapeutic advantage over placebo and to be well-tolerated, more patients will be recruited for Part B, where various dosages will be assessed. These dosages will be established based on results from Part A.

Condition or disease Intervention/treatment Phase
Rheumatoid Arthritis Drug: GLPG0259 oral capsule Drug: Placebo Drug: GLPG0259 (Part B) Drug: Placebo (Part B) Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized, Double-Blind, Placebo-Controlled, Multicenter, Exploratory Phase II Study to Compare Three Dose Regimens of GLPG0259 vs Placebo, in Combination With Methotrexate, Administered for 12 Weeks to Subjects With Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Study Start Date : October 2010
Actual Primary Completion Date : April 2011
Actual Study Completion Date : April 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: GLPG0259 (Part A) Drug: GLPG0259 oral capsule
Two capsules, each containing 25 mg of GLPG0259 (i.e. 50 mg/day), to be given once daily; in case of adverse events the dose may be split over two administrations, or reduced to 25 mg/day (one single capsule)

Placebo Comparator: Placebo (Part A) Drug: Placebo
Placebo capsules; two capsules to be taken in the morning, in case of adverse events the dose may be split over two administrations, or reduced to one single capsule

Experimental: GLPG0259 (Part B) Drug: GLPG0259 (Part B)
Capsule, dosage to be established based on results of Part A

Placebo Comparator: Placebo (Part B) Drug: Placebo (Part B)
Capsules, dosage to be established after Part A, and matching GLPG0259 (Part B)

Primary Outcome Measures :
  1. Efficacy [ Time Frame: 12 weeks ]
    The primary efficacy endpoint will be the number and percentage of subjects in each GLPG0259 dose group and placebo group achieving an American College of Rheumatology (ACR)20 (ACR20 response rate) at Week 12.

Secondary Outcome Measures :
  1. Efficacy [ Time Frame: intermediate timepoints for 12 weeks ]
    ACR20, ACR50, ACR75 and DAS28 (and components) at weeks 1, 2, 4, 8 and 12;

  2. Safety [ Time Frame: 12 weeks ]
    At each return visit, patients will be asked about adverse events, and undergo examination of heart (ECG) and bloodpressure; blood- and urine-samples will be collected to monitor organ functions.

  3. Pharmacokinetics [ Time Frame: 12 weeks ]
    On several timepoints throughout the study bloodsamples will be taken from the patient to establish the amount of the study medication in the blood, and to determine how long it stays in the blood.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must have active RA (≥5 tender or painful joints on motion and ≥5 joints swollen AND a C-reactive protein (CRP) concentration ≥1.5 mg/dL).
  • Must have been on methotrexate for ≥6 months at a stable dose of 7.5-25 mg/week for ≥12 weeks, to be continued throughout study;
  • If on oral steroids, these should be at a dose ≤10 mg/day of prednisone eq and stable for ≥4 weeks prior to screening;
  • If on NSAIDs, these must be at a stable dose for ≥2 weeks prior to screening;
  • Women must have negative pregnancy test unless surgically sterile or post-menopausal for ≥1 year;
  • Women of childbearing potential must use a medically acceptable means of birth control and agree to continue its use during the study and for ≥12 weeks after the last dose of study drug.
  • Informed consent

Exclusion Criteria:

  • Must not have received treatment with DMARDs, other than background methotrexate;
  • Must not be receiving or have received RA treatment with a biological agent, except if administered in a clinical study ≥six months prior to screening (12 months for rituximab or other B cell depleting agents);
  • Must not have received any treatment with a cytotoxic agent, other than methotrexate, before screening (e.g. chlorambucil, cyclophosphamide, nitrogen mustard, or other alkylating agents);
  • Must not have received intra-articular or parenteral corticosteroid injection within four weeks prior to screening;
  • Must not regularly be using aspirin or any other anti-coagulant medication;
  • Must not have a known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug as determined by the Investigator, such as anaphylaxis, requiring hospitalization;
  • Must not have positive serology for human immunodeficiency virus (HIV)1 or 2 or hepatitis B or C, or any history of HIV or hepatitis from any cause with the exception of hepatitis A;
  • Must not have a history of any inflammatory rheumatological disorders other than RA;
  • Must not have undergone (or planned) surgical treatments for RA;
  • Must not have symptoms of clinically significant illness other than RA (including but not limited to cardiopulmonary, renal, metabolic, hematologic, or psychiatric disorders) within three months prior to screening;
  • Must not have a history of active infections requiring intravenous antibiotics within the past four weeks;
  • Must not have a history of malignancy within the past five years (except for basal cell carcinoma of the skin or carcinoma in situ of the cervix that has been treated with no evidence of recurrence);
  • Must not have a history of tuberculosis (TB) infection as determined by a positive diagnostic TB test result (defined as a positive QuantiFERON TB Gold test), AND a recent chest radiograph (both posterior-anterior and lateral views), read by a qualified radiologist, with evidence of current active TB or old inactive TB.
  • Must not have been administered a live vaccine within four weeks prior to screening;
  • Must not have participated in any investigational drug/device clinical study within four weeks prior to screening, in biological agents clinical studies within six months prior to screening, and B cell-depleting agent clinical studies within 12 months prior to screening;
  • Must not have a history within the previous two years or current evidence of drug or alcohol abuse;
  • Must not have any condition or circumstances which in the opinion of the Investigator may make a subject unlikely or unable to complete the study or comply with study procedures and requirements, or may pose a risk to the patient's safety.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01211249

Show Show 32 study locations
Sponsors and Collaborators
Galapagos NV
Layout table for investigator information
Study Director: Johan Beetens, PhD Galapagos NV

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Senior Vice President Development, Galapagos NV Identifier: NCT01211249    
Other Study ID Numbers: GLPG0259-CL-201
2009-015898-12 ( EudraCT Number )
First Posted: September 29, 2010    Key Record Dates
Last Update Posted: April 26, 2011
Last Verified: April 2011
Keywords provided by Galapagos NV:
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunosuppressive Agents
Immunologic Factors
Antirheumatic Agents
Nucleic Acid Synthesis Inhibitors